Engineered immune cells take aim at a rare Protein-Clogging disease
NCT ID NCT06097832
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests a new treatment called NXC-201 CAR-T for people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The therapy uses a patient's own immune cells, modified to target and destroy the cells producing these proteins. The trial is open to adults whose disease has returned or not responded to prior treatments, and it aims to find a safe dose and measure how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NXC-201 CAR-T cell therapy
- What this could lead to
- If successful, this could offer a new treatment option for people with AL amyloidosis whose disease has returned or not responded to other therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and neurological side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT CHAIN (AL) AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Memorial Hospital
Memphis, Tennessee, 381202127, United States
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Boston University Medical Center
Boston, Massachusetts, 02118, United States
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Memorial Sloan Kettering Comprehensive Cancer Center
New York, New York, 10065, United States
-
Stanford University
Stanford, California, 94305, United States
-
Sutter Health Alta Bates
Berkeley, California, 94704, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Cincinnati Cancer Center
Cincinnati, Ohio, 45267, United States
-
Washington University Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.